referenties

voorkom orale mucositis met Caphosol

  1. Sonis ST, J Support Oncol. 2007;5(suppl4):3-11
  2. Murphy BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol. 2007;5(suppl 4):13-21.
  3. Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004;2(suppl 3):3-8.
  4. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 Suppl):2026-46.
  5. Köstler WJ et al. Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment. CA Cancer J Clin 2001;51:290-315.
  6. Sonis ST et al for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer. Perspectives on cancer therapy-induced mucosal injury. Cancer 2004;100:1995- 2025.
  7. Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. Review.
  8. Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009;45:1015-20.
  9. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008;6 Suppl 1:S1-21.
  10. Blijlevens N et al. Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008;26:1519-25.
  11. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2:21-32.
  12. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-84.
  13. Bensadoun RJ et al. Mucite radio-induite des voies aérodigestives : prévention et prise en charge Recommandations du groupe Mucites MASCC/ISOO. Bull Cancer 2006;93:201-11.
  14. Eilers J. Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. Oncol Nurse Forum 2004;31:13-23.
  15. Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;8:705-12.
  16. Miyamoto C et al. Support Care Cancer 2009; 17:857-1039. A retrospective study of 21 head and neck cancer patients treated with intensity-modulated radiation therapy (IMRT) who received Caphosol from the start of their treatment. Outcomes were compared with 21 matched control patients who received standard care for oral mucositis.
  17. Pico JL, Avila-Garavito A, Naccache P. Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting. Oncologist 1998;3:446-451.
  18. McGuire DB et al. Oncol Nurs Forum 1993;20:1493-1502
  19. Kröger N et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001;27:349-54.
  20. Zander AR et al. High dose chemotherapy with busulfan, cyclophosphamide and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997;3:2671-5.
  21. Gabriel DA et al. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant 2005;11:1022-30.
  22. Rosenthal MA, Grigg AP, Sheridan WP. High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. Leuk Lymphoma 1994;14:279-83.
  23. Patte C et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.Blood 2007;109:2773-80.
  24. Sonis S, Treister N. Oral mucositis. Davies A, Epstein J (Eds). Oral Complications of Cancer and it's management (1st edition). OUP Oxford, 2010.
  25. Avritscher EB et al. Semin Oncol Nurs 2004;20:3-10
  26. McCann S, Schwenkglenks M, Bacon P et al. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. BMT 2008;10:1038.
  27. Bruce SD, Quinn A. The pain of oral mucositis. US Oncological Disease 2007;1:86-90.
  28. Trotti A, Bellm LA, Epstein JB. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radioth and Oncol 2003;66:253-62.
  29. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-5.
  30. Elting LS et al. The Burdens of Cancer Therapy Clinical and Economic Outcomes of Chemotherapy-Induced Mucositis. Cancer 2003;98:1531-9.
  31. Daily Mail. Available at: http://www.dailymail.co.uk/health/article-1246082/New-mouthwasheases-discomfort-chemotherapy-preventing-treating-mouth-throat-ulcers.html. Accessed August 2010.
  32. Greenlight International. Oral Mucositis Patient Survey. Data on file, EUSA Pharma (Europe) Ltd. September 2010.
  33. Caphosol® Patient Information Leaflet. EUSA Pharma (Europe) Limited, November 2008
  34. Haas M et al. 50th ASTRO congress 2008; abstract 2530
  35. Haas ML et al. Reduction of Painful Oral Mucositis by Supersaturated Calcium Phosphate Oral Rinse in Head and Neck Cancer Patients Receiving Chemotherapy and Radiation. Presented at ASTRO. 2008.
  36. Rzepecki P et al. Use of a calcium phosphate mouth rinse for prevention of oral mucositis after haematopoietic stem cell transplantation: single-centre experience. Bone Marrow Transplantation March 2010;45:S109.
  37. Murao, E et al. Finally something good. Presented at EBMT. 2009
  38. Cannas, G et al. Caphosol, an electrolytic mouth rinse solution, reduces the incidence of Oral Mucositis in allogenic bone marrow transplantation. A pilot study in Lyon. Presented at SFGM-TC. 2009.
  39. Feyer, P et al. Caphosol experience with supersaturated calcium phosphate solution (Caphosol) for prophylaxis and treatment of oral mucositis in patients with head and neck tumours undergoing radio and/or chemotherapy. Presented at ASORS. 2009.
  40. Markiewicz, M et al. Caphosol mouth rinse diminishes oral mucositis in ALLO-HSCT recipients. Presented at ASH. 2010.
  41. Nguyen, T et al. Audit of the effectiveness of Caphosol mouthwash in Multiple Myeloma patients receiving Autologus Transplant with High Dose Melphalan at St Bartholomew's Hospital. Presented at BOPA. 2010.
  42. Data on file EUSA Pharma.
  43. Harousseau J-L et al. EBMT 2005, March 20-23; Prague, Czech Republic; Abstract & Poster
  44. Anthony L et al. Support Care Cancer 2006;14:516-518
  45. Gandemer V et al. Multicenter randomized trial of chewing gum for preventing oral mucositis in children receiving chemotherapy. J Pediatr Hematol Oncol 2007;29:86-94.
  46. Redding SW. J Dent Educ 2005;69:919-929
  47. Brown CG, Wingard J. Sem Oncol Nurs. 2004;20:16-21.
EUSAPharma Caphosol
® Caphosol is een geregistreerd merk van EUSA Pharma